Get the Stockscreener App
2.60
0.39%
0.01
After Hours:
2.59
-0.01
-0.38%
Immunitybio Inc stock is traded at $2.60, with a volume of 7.70M.
It is up +0.39% in the last 24 hours and up +5.26% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.59
Open:
$2.58
24h Volume:
7.70M
Relative Volume:
0.92
Market Cap:
$2.46B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.6804
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+8.33%
1M Performance:
+5.26%
6M Performance:
-9.41%
1Y Performance:
-25.50%
1-Day Range:
$2.54
$2.62
1-Week Range:
$2.32
$2.67
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.60 | 2.43B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Why ImmunityBio Inc. stock remains a top recommendationJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX) - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 7.3%Should You Buy? - MarketBeat
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking (NASDAQ:IBRX) - Seeking Alpha
Breakthrough Findings from Phase 2 QUILT-3.055 Study in NSCLCImmunityBio, Inc. - Oncodaily
ImmunityBio (NASDAQ:IBRX) Given Buy Rating at D. Boral Capital - MarketBeat
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
H.C. Wainwright reiterates Buy rating on ImmunityBio stock, citing promising lung cancer data - Investing.com Canada
ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer? - MSN
Sentiment Review: Is ImmunityBio Inc. a cyclical or defensive stock2025 Momentum Check & AI Forecasted Entry/Exit Points - Lancaster City Council
ImmunityBio Stock Rebounds: Bright Outlook Ahead? - StocksToTrade
ImmunityBio’s Stock Surge: Health Revolution or Hype? - timothysykes.com
ImmunityBio’s Surprising Performance: What Lies Ahead? - StocksToTrade
Decliners Report: Is ImmunityBio Inc. gaining market shareMarket Sentiment Summary & Fast Moving Trade Plans - Lancaster City Council
Risk Hedge: Does ImmunityBio Inc. have a sustainable dividendJuly 2025 Volume & Long Hold Capital Preservation Tips - Lancaster City Council
ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - BioSpace
ImmunityBio Inc. Shows Early Signs of Technical StrengthQuarterly Performance Summary & Technical Pattern Alert System - beatles.ru
Investors Can Still File Late Claims in ImmunityBio Settlement — Here’s How to Get Your Share - TradingView
Is ImmunityBio Inc. stock technically oversoldM&A Rumor & Weekly Top Performers Watchlists - beatles.ru
ImmunityBio’s Anktiva: A Promising Treatment for Long COVID? - TipRanks
Real time scanner hits for ImmunityBio Inc. explainedWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
What momentum shifts mean for ImmunityBio Inc.Analyst Downgrade & Consistent Profit Trade Alerts - Newser
A Closer Look at ImmunityBio (IBRX) Valuation Following Promising Early Results in Glioblastoma Study - Yahoo Finance
Rafferty Asset Management LLC Lowers Stock Holdings in ImmunityBio, Inc. $IBRX - MarketBeat
Is ImmunityBio Inc. gaining market shareMarket Trend Report & Weekly Chart Analysis and Guides - خودرو بانک
Is ImmunityBio Inc. a speculative investment2025 Key Highlights & Free Fast Gain Swing Trade Alerts - 강소기업뉴스
Is ImmunityBio Inc. reversing from oversold territoryJuly 2025 Reactions & Technical Entry and Exit Alerts - Newser
ImmunityBio Inc. stock volume spike explainedJuly 2025 Action & Momentum Based Trading Ideas - Newser
How to build a custom watchlist for ImmunityBio Inc.Gap Down & Weekly High Return Forecasts - Newser
What’s next for ImmunityBio Inc. stock price2025 Biggest Moves & Daily Stock Trend Watchlist - Newser
Advanced analytics toolkit walkthrough for ImmunityBio Inc.Weekly Investment Recap & Weekly Breakout Stock Alerts - Newser
Applying chart zones and confluence areas to ImmunityBio Inc.Quarterly Portfolio Report & Expert Curated Trade Setups - Newser
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates - MSN
ImmunityBio Inc. stock prediction for this week2025 Top Gainers & Technical Confirmation Trade Alerts - Newser
Using R and stats models for ImmunityBio Inc. forecasting2025 Price Action Summary & Low Risk Entry Point Tips - Newser
Will ImmunityBio Inc. bounce back from current supportJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
NK Cell Therapy Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies - The Globe and Mail
Osteoarthritis Pipeline Analysis, 2025 by DelveInsight | ImmunityBio, Five Prime Therapeutics, Innate Pharma, Nektar Therapeutics, Cantargia, CureTech, Dynavax, Cellid Company, Kiadis Pharma, Multimmu - Barchart.com
What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView
Detecting price anomalies in ImmunityBio Inc. with AIJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - Newser
Is ImmunityBio Inc. stock entering bullish territory2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
Measuring ImmunityBio Inc.’s beta against major indicesMarket Rally & Long-Term Growth Stock Strategies - Newser
Aug Sentiment: Can ImmunityBio Inc. stock double in the next yearWeekly Risk Summary & Advanced Technical Signal Analysis - خودرو بانک
Custom strategy builders for tracking ImmunityBio Inc.Bull Run & Technical Confirmation Trade Alerts - Newser
Should I hold or sell ImmunityBio Inc. nowJuly 2025 Action & High Accuracy Buy Signal Tips - خودرو بانک
Is ImmunityBio Inc. stock a smart retirement pickJuly 2025 Volume & Momentum Based Trading Ideas - khodrobank.com
What are the analyst revisions for DRUGIs ImmunityBio Inc. stock a good investment in YEARTrade Exit Summary & Real-Time Volume Analysis - خودرو بانک
Should value investors consider ImmunityBio Inc.July 2025 Sector Moves & Precise Trade Entry Recommendations - خودرو بانک
Can ImmunityBio Inc. stock double in the next year2025 Market Overview & AI Driven Price Predictions - خودرو بانک
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):